P380: Changes in faecal microbiome and metabolome are more pronounced in Crohn's disease patients who adhered to the CD-TREAT diet and responded by calprotectin.ECCO’23 CopenhagenYear: 2023
Authors: Svolos, V.(1)*;Hansen, R.(2);Russell, R.K.(3);Gaya, D.R.(4);John Paul, S.(5);Macdonald, J.(5);Wilson, D.(3);Henderson, P.(3);Din, S.(6);Ho, G.T.(6);Quince, C.(7);Ijaz, U.Z.(8);Milling, S.(9);Nichols, B.(1);Papadopoulou, R.(1);McKirdy, S.(1);Gervais, L.(2);Shields, S.(5);Gerasimidis, K.(1);
(1)University of Glasgow, Human Nutrition- School of Medicine- Dentistry & Nursing- College of Medical- Veterinary and Life Sciences, Glasgow, United Kingdom;(2)Royal Hospital for Children, Department of Paediatric Gastroenterology- Hepatology and Nutrition, Glasgow, United Kingdom;(3)Royal Hospital for Children and Young People, Department of Paediatric Gastroenterology, Edinburgh, United Kingdom;(4)Glasgow Royal Infirmary, Department of Gastroenterology, Glasgow, United Kingdom;(5)Queen Elizabeth University Hospital, Department of Gastroenterology, Glasgow, United Kingdom;(6)Western General Hospital, Edinburgh IBD Unit- Department of Gastroenterology, Edinburgh, United Kingdom;(7)Norwich Research Park, Earlham Institute, Norwich, United Kingdom;(8)University of Glasgow-, School of Engineering, Glasgow, United Kingdom;(9)University of Glasgow, Institute of Infection- Immunity and Inflammation- College of Medical- Veterinary and Life Sciences, Glasgow, United Kingdom;
P382: Serum Ustekinumab Concentrations are Associated with Improved Outcomes with the Magnetic Resonance Index of Activity for Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Chen, K.(1,2)*;Chen, J.(3);Smith, E.(1,2);Mathani, P.(1,2);Longman, R.(1,2);Lukin, D.(1,2);Scherl, E.(1,2);Battat, R.(1,2);
(1)Weill Cornell Medicine, Division of Gastroenterology- Department of Medicine, New York, United States;(2)Weill Cornell Medicine, Jill Roberts Center for Inflammatory Bowel Disease, New York, United States;(3)Weill Cornell Medicine, Department of Radiology, New York, United States;
P383: Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry.ECCO’23 CopenhagenYear: 2023
Authors: Iborra Colomino, M.I.(1)*;Garrido Marín, A.(1);Caballol Oliva, B.(2);Huguet Malavés, J.M.(3);Arias García, L.(4);Mesonero Gismero, F.(5);Fernández Prada, S.J.(6);Boscá Watts, M.M.(7);Ponferrada Díaz, Á.(8);Calvet Calvo, X.(9);Gutiérrez Casbas, A.(10); Ordás Jiménez, I.(2);Ruiz Sanchez, L.(3);Sicilia Aladren, B.(4);Garcia de la Filia, I.(5);Domènech Morral, E.(11);Nos Mateu, P.(1);
(1)Hospital Universitario y Politécnico la Fe de Valencia, Gastroenterology, Valencia, Spain;(2)Hospital Clínic de Barcelona, Gastroenterology, Barcelona, Spain;(3)Consorcio Hospital General Universitario de Valencia, Gastroenterology, Valencia, Spain;(4)Hospital Universitario de Burgos, Gastroenterology, Burgos, Spain;(5)Hospital Universitario Ramón y Cajal, Gastroenterology, Madrid, Spain;(6)Hospital Universitario Río Hortega de Valladolid, Gastroenterology, Valladolid, Spain;(7)Hospital Clínico Universitario de Valencia, Gastroenterology, Valencia, Spain;(8)Hospital Universitario Infanta Leonor Madrid, Gastroenterology, Madrid, Spain;(9)Hospital Universitari Parc Taulí, Gastroenterology, Sabadell, Spain;(10)Hospital General Universitario de Alicante Doctor Balmis, Gastroenterology, Alicante, Spain;(11)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;
P384: A higher red blood cell methotrexate polyglutamate 3 concentration is associated with methotrexate drug-survival in patients with Crohn's Disease: first results of a prospective cohortECCO’23 CopenhagenYear: 2023
Authors: Van De Meeberg, M.(1)*;Fidder, H.(2);Sundaresan, J.(3);Struys, E.(3);Oldenburg, B.(2);Mares, W.(4);Mahmmod, N.(5);van Asseldonk, D.(6);Lutgens, M.(7);Kuyvenhoven, J.(8);Rietdijk, S.(9);Nissen, L.(10);Koehestanie, P.(11);de Jonge, R.(3);Bulatović Ćalasan, M.(12);Bouma, G.(13);
(1)Amsterdam UMC, Department of Gastroenterology, Amsterdam, The Netherlands;(2)UMC Utrecht, Department of Gastroenterology and Hepatology, Utrecht, The Netherlands;(3)Amsterdam UMC, Department of Clinical Chemistry, Amsterdam, The Netherlands;(4)Gelderse Vallei Hospital, Department of Gastroenterology and Hepatology, Ede, The Netherlands;(5)Sint Antonius Hospital, Department of Gastroenterology and Hepatology, Nieuwegein, The Netherlands;(6)Noordwest Hospital, Department of Gastroenterology and Hepatology, Alkmaar, The Netherlands;(7)Elizabeth - Tweesteden Hospital, Department of Gastroenterology and Hepatology, Tilburg, The Netherlands;(8)Spaarne gasthuis, Department of Gastroenterology and Hepatology, Hoofddorp, The Netherlands;(9)OLVG, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;(10)Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, 's Hertogenbosch, The Netherlands;(11)Bravis Hospital, Department of Gastroenterology and Hepatology, Roosendaal, The Netherlands;(12)UMC Utrecht, Department of Rheumatology and Clinical Immunology, Utrecht, The Netherlands;(13)Amsterdam UMC, Department of Gastroenterology and Hepatology, Amsterdam, The Netherlands;Dutch Initiative on Crohn and Colitis (ICC)
P385: Risk-benefit assessment of IBD drugs: a physicians and patients surveyECCO’23 CopenhagenYear: 2023
Authors: D'Amico, F.(1)*;Caron, B.(2);Vieujean, S.(3);Peyrin-Biroulet, L.(2);Danese, S.(1);
(1)IRCCS San Raffaele Hospital, Gastroenterology and Endoscopy, Milan, Italy;(2)University of Lorraine, Inserm- NGERE, F-54000 Nancy, France;(3)University Hospital CHU of Liège, Hepato-Gastroenterology and Digestive Oncology, Liège, Belgium;
P386: Clinical presentation, management, and evolution of lymphomas in patients with Inflammatory Bowel Disease: an ENEIDA registry study.ECCO’23 CopenhagenYear: 2023
Authors: Guerra Marina, I.(1)*;Bujanda, L.(2,3);Mañosa, M.(3,4);Pérez-Martínez, I.(5);Casanova, M.J.(3,6);de la Peña, L.(7);de Benito, M.(8);Rivero, M.(9);Varela, P.(10);Bernal, L.(3,11);Franco, A.C.(12);Ber, Y.(13);Piqueras, M.(14);Tardillo, C.(15);Ponferrada, Á.(16);Olivares, S.(17);Lucendo, A.J.(18);Gilabert, P.(19);Sierra Ausín, M.(20);Bellart, M.(1);Herrarte, A.(2);Calafat, M.(3,4);de Francisco, R.(5);P. Gisbert, J.(3,6);Guardiola, J.(7);Domènech, E.(3,4);Bermejo, F.(1);
(1)Hospital Universitario de Fuenlabrada, Gastroenterology, Fuenlabrada, Spain;(2)Hospital Donostia/Instituto Biodonostia- Universidad del País Vasco UPV/EHU, Gastroenterology, Donostia-San Sebastián, Spain;(3)Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas CIBEREHD, Gastroenterology, Spain, Spain;(4)Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain;(5)Hospital Universitario Central de Asturias and Instituto de Investigación Sanitaria del Principado de Asturias ISPA, Gastroenterology, Oviedo, Spain;(6)Hospital Universitario de La Princesa- IIS-Princesa- Universidad Autónoma de Madrid UAM, Gastroenterology, Madrid, Spain;(7)Hospital Universitari de Bellvitge- Institut d'Investigació Biomèdica de Bellvitge IDIBELL- Universitat de Barcelona, Gastroenterology, l´Hospitalet de Llobregat, Spain;(8)Hospital Universitario Río Hortega, Gastroenterology, Valladolid, Spain;(9)Hospital Universitario Marqués de Valdecilla and IDIVAL, Gastroenterology, Santander, Spain;(10)Hospital Universitario de Cabueñes, Gastroenterology, Gijón, Spain;(11)Hospital General Universitario Dr Balmis de Alicante, Gastroenterology, Alicante, Spain;(12)Hospital Universitario de Fuenlabrada, Onco-Hematology, Fuenlabrada, Spain;(13)Hospital General San Jorge, Gastroenterology, Huesca, Spain;(14)Consorci Sanitari Terrassa, Gastroenterology, Terrassa, Spain;(15)Hospital Universitario Nuestra Señora de la Candelaria, Gastroenterology, Tenerife, Spain;(16)Hospital Universitario Infanta Leonor, Gastroenterology, Madrid, Spain;(17)Hospital 12 de Octubre, Gastroenterology, Madrid, Spain;(18)Hospital General de Tomelloso, Gastroenterology, Ciudad Real, Spain;(19)Hospital de Viladecans, Gastroenterology, Barcelona, Spain;(20)Complejo Asistencial Universitario de León, Gastroenterology, León, Spain;On behalf of the ENEIDA project of GETECCU.
P387: Different rate of transmural remission between first and second line of biologic treatment in Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: De Sire, R.(1)*;Rispo, A.(1);Caiazzo, A.(1);Testa, A.(1);Nardone, O.M.(1);Guarino, A.D.(1);Olmo, O.(1);Calabrese, G.(1);Fierro, G.(1);Toro, B.(1);Cantisani, N.M.(1);Ferrante, M.(1);La Mantia, A.(1);D'Alessandro, E.(1);Castiglione, F.(1);
(1)University Federico II of Naples, Department of Clinical Medicine and Surgery, Naples, Italy;
P388: Shear wave elastography predicts short-term response to induction therapy in patients with Crohn's diseaseECCO’23 CopenhagenYear: 2023
Authors: Sagami, S.(1,2)*;Morikubo, H.(1,2);Miyatani, Y.(1);Fukuda, T.(1,2);Asonuma, K.(1);Maeda, M.(1,2);Yoko, Y.(1,2);Karashima, R.(1,2);Hojo, A.(1,2);Nakano, M.(1,2);Hibi, T.(1);Kobayashi, T.(1,2,3);
(1)Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan;(2)Kitasato University Kitasato Institute Hospital, Department of Gastroenterology, Tokyo, Japan;(3)Kitasato University School of Medicine, Department of Gastroenterology, Kanagawa, Japan;
P389: Switching infliximab to subcutaneous from intravenous therapy (SWIMSUIT) – A prospective, real-world, single centre, phase IV interventional study.ECCO’23 CopenhagenYear: 2023
Authors: Rahmany, S.(1)*;Young, D.(1);Moyses, H.(2);Gonclaves, J.(3);Latter, S.(4);Cummings, F.(1,5);
(1)University Hospital Southampton NHS Foundation Trust, Gastroenterology, Southampton, United Kingdom;(2)University Hospital Southampton NHS Foundation Trust, NIHR Biomedical Research Centre, Southampton, United Kingdom;(3)University of Lisbon, iMed – Research Institute for Medicines- Department of Pharmacy, Lisbon, Portugal;(4)University of Southampton, School of Health Sciences, Southampton, United Kingdom;(5)University of Southampton, Faculty of Medicine, Southampton, United Kingdom;
P390: Ustekinumab modulates IL-12 and IL-23-related cell type-specific inflammatory transcriptional states in Ulcerative Colitis induction therapyECCO’23 CopenhagenYear: 2023
Authors: Richards, D.(1)*;Venkat, S.(1);Freeman, T.C.(1);Mcrae, B.(1);Hoops, T.(1);Marano, C.(1);Branigan, P.(1);
(1)Janssen Research & Development- LLC, Translational Sciences- Immunology, Spring House, United States;
P391: Relative association of bowel urgency clinically meaningful improvement or bowel urgency remission versus stool frequency remission and rectal bleeding remission with improvement in Inflammatory Bowel Disease Questionnaire scores in patients with moderately-to-severely active Ulcerative Colitis: An analysis from LUCENT-1 and LUCENT-2 phase 3 clinical trialsECCO’23 CopenhagenYear: 2023
Authors: Sands, B.E.(1)*;Feagan, B.(2,3);Gibble, T.H.(4);Keohane, A.(4);Eastman, W.(4);Traxler, K.(4);Schreiber, S.(5);Jairath, V.(6);Armuzzi, A.(7);
(1)Icahn School of Medicine- Mount Sinai, Dr. Henry D. Janowitz Division of Gastroenterology, New York, United States;(2)Alimentiv- Inc, Clinical research, London- Ontario, Canada;(3)Western University, Gastroenterology, London- Ontario, Canada;(4)Eli Lilly and Company, Immunology, Indianapolis, United States;(5)University Hospital Schleswig-Holstein- Kiel University-, Clinic for Internal Medicine I, Kiel, Germany;(6)University Hospital, Department of Medicine, London- Ontario, Canada;(7)Humanitas Research Hospital- Rozzano, Gastroenterology, Milan, Italy;
P392: Risk factors for postoperative recurrence after ileocolic resection for Crohn's Disease: long-term results from a population-based cohort.ECCO’23 CopenhagenYear: 2023
Authors: van Renterghem, A.(1)*;van der Holst, A.(1);van Kuijk, S.(2);Pierik, M.(3);Belgers, E.(4);Romberg-Camps, M.(5);Jeuring, S.(3);Demandt, D.(1);Stassen, L.(1);
(1)Maastricht University Medical Centre +, Surgery, Maastricht, The Netherlands;(2)Maastricht University Medical Centre +, Epidemiology, Maastricht, The Netherlands;(3)Maastricht University Medical Centre +, Gastroenterology, Maastricht, The Netherlands;(4)Zuyderland Medical Centre, Surgery, Heerlen, The Netherlands;(5)Zuyderland Medical Centre, Gastroenterology, Heerlen, The Netherlands;
P393: Effect of filgotinib on anaemia in patients with Ulcerative Colitis in SELECTIONECCO’23 CopenhagenYear: 2023
Authors: Loveikyte, R.(1)*;de Haas, A.(2);Oortwijn, A.(3);Eskens, B.(3);Jamoul, C.(4);Muller, K.(4);van der Meulen-de Jong, A.(5);
(1)Leiden University Medical Center LUMC, Gastroenterology and Hepatology, Leiden, The Netherlands;(2)Galapagos NV, Clinical Development Department, Leiden, The Netherlands;(3)Galapagos NV, Medical Affairs Department, Leiden, The Netherlands;(4)Galapagos NV, Biostatistics Department, Mechelen, Belgium;(5)Leiden University Medical Center, Department of Gastroenterology and Hepatology, Leiden, The Netherlands;
P394: Long-term perineal reoperation and wound healing after proctectomy or ileal pouch-anal anastomosis extirpation in patients with Inflammatory Bowel Disease – a retrospective multicentre studyECCO’23 CopenhagenYear: 2023
Authors: Berghog, J.(1)*;Hermansson, M.(2);Risto, A.(3);Strömbäck, J.(4);Unger, D.(4);Gustafsson, H.(5);Hagavall, M.(6);Landerholm, K.(7);Buchwald, P.(8);Nordenvall, C.(9);Myrelid, P.(3);Block, M.(2);
(1)Institute of Clinical Sciences- Sahlgrenska Academy Gothenburg University- Gothenburg- Sweden, Department of Surgery- Sahlgrenska University Hospital/ Östra- Gothenburg- Sweden, Göteborg, Sweden;(2)Institute of Clinical Sciences- Sahlgrenska Academy Gothenburg University- Gothenburg- Sweden, Department of Surgery- Sahlgrenska University Hospital/Östra- Gothenburg- Sweden, Göteborg, Sweden;(3)Department of Clinical and Experimental Medicine- Linköping University- Linköping- Sweden, Department of Surgery- Linköping University Hospital- Linköping- Sweden, Linköping, Sweden;(4)Department of Molecular Medicine and Surgery- Karolinska Institutet- Stockholm- Sweden, Department of Molecular Medicine and Surgery- Karolinska Institutet- Stockholm- Sweden, Stockholm, Sweden;(5)Department of Surgery- Skåne University Hospital- Malmö- Sweden, Department of Surgery- Skåne University Hospital- Malmö- Sweden, Malmö, Sweden;(6)Department of Surgery- Ryhov county hospital- Jönköping- Sweden, Department of Surgery- Ryhov county hospital- Jönköping- Sweden, Jönköping, Sweden;(7)Department of Biochemical and Clinical Sciences- Linköping University- Linköping- Sweden, Department of Surgery- Ryhov county hospital- Jönköping, Jönköping, Sweden;(8)Department of Clinical Sciences Malmö- Lund University- Lund- Sweden, Department of Surgery- Skåne University Hospital- Malmö- Sweden, Malmö, Sweden;(9)Department of Molecular Medicine and Surgery- Karolinska Institutet- Stockholm- Sweden, Department of Pelvic Cancer- colorectal surgery unit- Karolinska University Hospital- Stockholm- Sweden, Stockholm, Sweden;Swedish Organization for the study of IBD (SOIBD)
P395: Short-term clinical efficacy and safety of teduglutide for Crohn's disease patients with short bowel syndromeECCO’23 CopenhagenYear: 2023
Authors: Kaku, K.(1)*;Sato, T.(1);Takeuchi, J.(2);Uchino , M.(3);Fujihira, Y.(1); Shimizu, K.(1);Yokoyama, K.(1);Yagi , S.(1);Takashima, Y.(1);Ikenouchi, M.(1);Kojima, K.(1);Kawai, M.(1); Nagase , K.(1);Kamikozuru, K.(1);Yokoyama , Y.(1);Takagawa, T.(1); Ikeuchi, H.(3);Watanabe, K.(1);Shinzaki , S.(1);
(1)Hyogo Medical University, Division of Gastroenterology and Hepatology- Department of Internal Medicine, Hyogo, Japan;(2)Hyogo Medical University, Department of Clinical Epidemiology, Hyogo, Japan;(3)Hyogo Medical University, Division of Surgery- Department of Inflammatory Bowel Disease, Hyogo, Japan;
P396: Ustekinumab Is A Promising Option For The Treatment Of Postoperative Recurrence Of Crohn's DiseaseECCO’23 CopenhagenYear: 2023
Authors: Macaluso, F.S.(1)*;Grova, M.(1);Mocciaro, F.(2);Di Mitri, R.(2);Privitera, A.C.(3);Distefano, M.E.(3);Vitello, A.(4);Camilleri, S.(4);Ferracane, C.(5);Pluchino, D.(5);Belluardo, N.(6);Giangreco, E.(6);Fries, W.(7);Viola, A.(7);Cappello, M.(8);Amato, L.(8);Bertolami, C.(9);Ventimiglia, M.(10);Renna, S.(1);Casà, A.(1);De Vivo, S.(1);Orlando, A.(1);
(1)Villa Sofia-Cervello Hospital, IBD Unit, Palermo, Italy;(2)“ARNAS Civico - Di Cristina – Benfratelli” Hospital, Gastroenterology and Endoscopy Unit, Palermo, Italy;(3)Cannizzaro Hospital, IBD Unit, Catania, Italy;(4)S. Elia- Raimondi Hospital, Gastroenterology and Endoscopy Unit, Caltanissetta, Italy;(5)Vittorio Emanuele Hospital, Gastroenterology Unit, Catania, Italy;(6)Guzzardi Hospital, Gastroenterology Unit, Vittoria, Italy;(7)G. Martino Hospital, IBD Unit, Messina, Italy;(8)University of Palermo, Gastroenterology & Hepatology Section- Promise, Palermo, Italy;(9)Papardo Piemonte Hospital, Gastroenterology Unit, Messina, Italy;(10)Italian Ministry of Health, Directorate General of Medical Device and Pharmaceutical Service, Rome, Italy;Sicilian Network for Inflammatory Bowel Disease (SN-IBD)
P397: Advanced therapy persistence and need for dose optimisation in a cohort of Inflammatory Bowel Disease patients in Argentina: a real-world evidence multicenter study (REMAR study)ECCO’23 CopenhagenYear: 2023
Authors: Lasa, J.(1)*;Nazario, E.(2);Zubiaurre, I.(2);Rausch, A.(2);Hermida, R.(3);Cassella, F.(4);Marzullo, S.(4);Suarez Pellegrino, A.(5);Deborah, B.(5);Toro, M.(5);Novillo, A.(6);Omodeo, J.(6);Tirado, P.(7);Bellicoso, M.(7);Olivera, P.(8);Balderramo, D.(9);Torello, R.(9);Chiaraviglio, L.(9);Scacchi, A.(3);Linares, M.(10);Gonzalez, R.(11);Bentolila, F.(11);Lubrano, P.(12);Quintero, O.(10);De Paula, J.(13);Gonzalez Sueyro, R.(13);Sanchez, B.(13);Fuxman, C.(14);Velazquez , A.(15);
(1)CEMIC, Gastroenterology, Buenos Aires, Argentina;(2)Hospital Británico, Gastroenterology, Buenos Aires, Argentina;(3)Hospital Churruca Visca, Gastroenterology, Buenos Aires, Argentina;(4)Sanatorio Guemes, Gastroenterology, Buenos Aires, Argentina;(5)HIGEA, Gastroenterology, Mendoza, Argentina;(6)Sanatorio 9 de Julio, Gastroenterology, San Miguel de Tucumán, Argentina;(7)Inmunología Buenos Aires, Gastroenterology, Buenos Aires, Argentina;(8)Zane Cohen Centre for Digestive Diseases- Lunenfeld-Tanenbaum Research Institute- Sinai Health System, Gastroenterology, Toronto, Canada;(9)Hospital Privado, Gastroenterology, Córdoba, Argentina;(10)Hospital de Clínicas, Gastroenterology, Buenos Aires, Argentina;(11)Hospital Alemán, Gastroenterology, Buenos Aires, Argentina;(12)Sanatorio Mater Dei, Gastroenterology, Buenos Aires, Argentina;(13)Hospital Italiano, Gastroenterology, Buenos Aires, Argentina;(14)Hospital Universitario Fundación Favaloro, Gastroenterology, Buenos Aires, Argentina;(15)Hospital Universitari Fundación Favaloro, Gastroenterology, Buenos Aires, Argentina;
P399: Detection of iron restricted erythropoiesis in patients with IBD: How can we disentangle effects of inflammation?ECCO’23 CopenhagenYear: 2023
Authors: Aksan, A.(1,2,3)*;Mangold, C.(4);Stötzel, J.(1,3);Tessmer, L.(3,5);Schröder, O.(3,5);Stein, J.M.(3,5,6);
(1)Justus-Liebig University Giessen, Institute of Nutritional Science, Giessen, Germany;(2)Immundiagnostik AG, Medical Affairs, Bensheim, Germany;(3)Interdisciplinary Crohn-Colitis Centre Rhein-Main, Clinical Research, Frankfurt am Main, Germany;(4)Goethe University Frankfurt, Faculty of Medicine, Frankfurt am Main, Germany;(5)DGD Clinics Sachsenhausen, Gastroenterology/Oncology, Frankfurt am Main, Germany;(6)Goethe University Frankfurt, Institute of Pharmaceutical Chemistry, Frankfurt am Main, Germany;
